Skip to Content

Generic Lamictal XR Availability

See also: Generic Lamictal, Generic Lamictal CD, Generic Lamictal ODT

Lamictal XR is a brand name of lamotrigine, approved by the FDA in the following formulation(s):

LAMICTAL XR (lamotrigine - tablet, extended release;oral)

Has a generic version of Lamictal XR been approved?

A generic version of Lamictal XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lamictal XR and have been approved by the FDA:

lamotrigine tablet, extended release;oral

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: October 17, 2013
    Strength(s): 100MG [AB], 200MG [AB], 25MG [AB], 50MG [AB], 300MG [AB]
  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: November 13, 2013
    Strength(s): 250MG [AB]
  • Manufacturer: AMNEAL PHARMS
    Approval date: November 30, 2018
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB], 250MG [AB], 300MG [AB]
  • Manufacturer: ANCHEN PHARMS
    Approval date: December 26, 2012
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB], 250MG [AB], 300MG [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: June 19, 2013
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB], 300MG [AB]
  • Manufacturer: PAR PHARM
    Approval date: January 18, 2013
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB], 250MG [AB], 300MG [AB]
  • Manufacturer: RUBICON
    Approval date: June 17, 2013
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: TORRENT
    Approval date: December 23, 2013
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB]
  • Manufacturer: WOCKHARDT LTD
    Approval date: January 4, 2013
    Strength(s): 25MG [AB], 50MG [AB], 100MG [AB], 200MG [AB], 300MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lamictal XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Formulations and method of treatment
    Patent 8,637,512
    Issued: January 28, 2014
    Assignee(s): Glaxo Group Limited

    A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.

    Patent expiration dates:

    • June 14, 2028
      Drug product
  • Oral dosage form for controlled drug release
    Patent 9,144,547
    Issued: September 29, 2015
    Assignee(s): Glaxo Group Limited

    An oral dosage form comprising, (i) an erodable core, which core comprises a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof; and (ii) an erodable coating surrounding said core, which coating comprises one or more openings extending substantially completely through said coating but not penetrating said core and communicating from the environment of use to said core; characterized in that release of the pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof from the dosage form occurs through the said opening(s) by the erosion of said erodable core and through erosion of said erodable coating under pre-determined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.

    Patent expiration dates:

    • September 22, 2023
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.